- 1 Safety of Repeated Low-Level Red-Light Therapy for Myopia: A Systematic
- 2 Review

5

10

- 4 **Running Title:** Safety of repeated low-level red-light therapy
- 6 Authors
- 7 Yanping Chen, MD<sup>1</sup>\*, Shida Chen, MD, PhD<sup>1</sup>\*, Ruilin Xiong, MD, PhD<sup>1</sup>\*, Shaopeng
- 8 Yang, MD<sup>1</sup>, Riqian Liu, MD<sup>1</sup>, Ziyu Zhu, MBBS<sup>1</sup>, Kaidi Xiang, MD<sup>2,3</sup>, Nathan
- 9 Congdon, MD, MPH<sup>1,4,5</sup>†, Wei Wang, MD, PhD<sup>1</sup>†

## 11 Affiliations

- 12 1. State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun
- 13 Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and
- 14 Visual Science, Guangdong Provincial Clinical Research Center for Ocular
- Diseases, Guangzhou, Guangdong, China.
- 16 2. Department of Clinical Research, Shanghai Eye Disease Prevention and
- 17 Treatment Center, Shanghai Eye Hospital, Shanghai Vision Health Center and
- Shanghai Children Myopia Institute, Shanghai, China.
- 19 3. Department of Ophthalmology, Shanghai General Hospital (Shanghai First
- 20 People's Hospital), Shanghai Jiao Tong University School of Medicine, Shanghai,
- 21 China; National Clinical Research Center for Eye Diseases; Shanghai Clinical
- 22 Research Center for Eye Diseases; Shanghai Key Clinical Specialty; Shanghai
- 23 Key Laboratory of Ocular Fundus Diseases; Shanghai Engineering Center for
- Visual Science and Photomedicine; Shanghai Engineering Center for Precise
- Diagnosis and Treatment of Eye Diseases, Shanghai Eye Research Institute,
- Shanghai, China.

- 27 4. Centre for Public Health, Queen's University Belfast, Belfast, United Kingdom.
- 5. Orbis International, New York, New York, United States of America.
- 29 \*Co-first authors. †Co-corresponding authors.

**Corresponding Author** 31 32 Wei Wang, MD PhD, Zhongshan Ophthalmic Center, State Key Laboratory of 33 Ophthalmology, Sun Yat-sen University, Guangzhou, China. Email: wangwei@gzzoc.com | ORCID: https://orcid.org/0000-0002-5273-3332 34 35 36 Nathan Congdon, MD, MPH, Zhongshan Ophthalmic Center, State Key Laboratory of 37 Ophthalmology, Sun Yat-sen University, Guangzhou, China; Centre for Public Health, 38 Queen's University Belfast, Belfast, United Kingdom; Orbis International, New York, 39 New York, United States of America. 40 Email: ncongdon1@gmail.com | ORCID: https://orcid.org/0000-0001-9866-3416 41 42 **Financial Support** 43 This research was supported by the National Natural Science Foundation of China 44 (82371086). The sponsors or funding organizations had no roles in the design or conduct of this research. 45 46 47 **Conflicts of Interests** 48 All authors declare no competing interests. 49 50 Word Count: [Abstract: 343 / Text: 3718] 51 Tables: 4 52 Figures: 2 53 **Supplementary Tables: 3** 54 55 **Abbreviations and Acronyms:** 56 RLRL = repeated low-level red-light; OCT = optical coherence tomography; CI = 57 confidence interval; IMI = International Myopia Institute; RCT = randomized 58 controlled trial; SER = spherical equivalent refraction; AL = axial length; NNH =

number needed to harm; NNT = number needed to treat; SVS = single-vision

spectacles; BCVA = best-corrected visual acuity.

59

62 **Abstract** 

63

65

79

81

84

91

**Topic:** Existing evidence for the safety of repeated low-level red-light (RLRL)

64 therapy for myopia control.

**Clinical relevance:** Recent trials show RLRL therapy is effective in the prevention

and control of myopia. Establishing its safety profile is necessary prior to widespread

67 clinical implementation.

68 **Methods:** We conducted a systematic review (International Prospective Register of

69 Systematic Reviews, CRD42024516676) of articles across seven databases from

inception through February 10, 2024, with keywords related to myopia and RLRL

71 therapy. Pooled safety outcomes and risk-to-benefit ratios were reported, and

72 incidence of side effects was compared with other anti-myopia interventions. Quality

appraisal was performed using the Cochrane Risk of Bias Tool.

74 **Results:** Among 689 screened articles, 20 studies (2.90%; eleven randomized

controlled trials, four non-randomized controlled trials, one post-trial study, one

single-arm study, one retrospective study and two case reports of identical patient.;

77 median duration 9 months, longest 24 months) were analysed, encompassing 2,380

78 participants aged 3-18 years and 1,436 individuals undergoing RLRL therapy. Two

case reports described an identical patient with reversible decline in visual acuity and

80 optical coherence tomography (OCT) abnormalities, completely resolved 4 months

after treatment cessation. No cases of permanent vision loss were reported. Temporary

82 afterimage was the most common ocular symptom following treatment, resolving

83 within 6 minutes in reported studies. The number needed to harm outweighed the

number needed to treat by a ratio of 12.7-21.4 for a person with -3D to -8D myopia

treated with RLRL therapy. Incidence of side effects from RLRL was 0.088 per 100

patient-years (95% confidence interval [CI], 0.02-0.50), comparable to spectacles

designed for myopia reduction (0.22; 95% CI, 0.09-0.51; P=0.385), and significantly

lower than for low-dose atropine (7.32; 95% CI, 6.65-8.05; P<0.001), orthokeratology

89 (20.6; 95% CI, 16.7-25.0; P<0.001), other anti-myopia contact lens (19.3; 95% CI,

90 17.6-21.1; P<0.001).

**Conclusion:** No irreversible visual function loss or ocular structural damage was

identified with RLRL. Fundus photography and OCT before and during therapy,
alongside home monitoring of visual acuity and duration of afterimages, are necessary
to identify side effects. Further adequately-powered studies of longer duration are
needed to evaluate long-term safety of RLRL.

Keywords: Refractive error, myopia prevention, repeated low-level red-light, safety,
risk-to-benefit

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

Introduction Myopia is the most common ocular disorder of childhood and adolescence. Without effective intervention measures, it is estimated that approximately 50% of the global population will be affected by 2050. The rising prevalence of myopia, along with earlier onset, increases the risk of high myopia, which may be associated with irreversible, sight-threatening complications such as myopic maculopathy, glaucoma and retinal detachment.<sup>2-4</sup> Therefore, prevention and control of myopia have become important public health challenges. Repeated low-level red-light (RLRL) therapy, highlighted in the latest 2023 Digest of the International Myopia Institute (IMI), has emerged as a novel approach to myopia prevention.<sup>5</sup> RLRL therapy involves locally irradiating the retina with low-level red light (approximately 1600 lux). It falls under Group 1 of the ANSI Z80.36-2021 standard, ensuring its safety for clinical ophthalmic applications. Unlike traditional therapeutic lasers such as panretinal photocoagulation, which rely on thermal effects generated through transpupillary energy ranging from 200-250 mW passing through the pupil, RLRL uses a much lower energy level of 0.29 mW, avoiding any thermal effects. Its therapeutic impact is postulated to rely on photobiomodulation (PBM) secondary to the laser's energy, potentially leading to thickening of the choroidal layer.7 Growing trial evidence supports the effectiveness of RLRL therapy in reducing myopia progression. The first multicenter randomized controlled trial (RCT) in China demonstrated in 2019 that home-based RLRL therapy, administered for 3 minutes twice daily for 5 days a week, significantly reduced axial elongation by 69.4% and refractive progression by 76.6% among school-aged children. Subsequent clinical trials have consistently confirmed these findings. 9-11 Recently, a meta-analysis incorporating 13 studies comprising 8 RCTs, 3 non-randomized controlled trials and 2 cohort studies, and involving a total of 1857 children and adolescents, confirmed the efficacy of RLRL therapy. <sup>12</sup> Six-month weighted differences in spherical equivalent

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

refraction (SER) and axial length (AL) were 0.68 diopters (D) and 0.35 mm respectively between the RLRL treatment group and controls. However, published studies have predominantly focused on efficacy outcomes, with limited reporting of the safety and side effects of RLRL therapy. To address this important knowledge gap, we systematically reviewed the safety profiles and risk-to-benefit ratio associated with RLRL treatment for myopia prevention and control. The aim of this study is to provide insights to help both clinicians and program designers optimize use of RLRL therapy, ensuring its safe and effective integration into myopia management. Methods This review was registered prospectively on the International Prospective Register of Systematic Reviews database (available from https://www.crd.york.ac.uk/prospero/display\_record.php?ID=CRD42024516676) and is reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. 13 All research adhered to the tenets of the Declaration of Helsinki. Individual patient-level consent was not required, nor was ethical review. **Eligibility Criteria** We included clinical studies of RLRL therapy designed to prevent myopia or delay its progression. Studies were selected according to the following criteria: (1) Participants were younger than 18 years with myopia or premyopia; (2) RLRL therapy was used in at least one arm or by all participants; (3) Reporting of at least 1 safety outcome, including visual function, ocular structural assessment, or adverse events; (4) All study types except literature reviews, in order to capture as many reported safety profiles and side effects as possible. We excluded studies on non-human subjects, those enrolling participants with secondary myopia, without safety data, and those merely describing treatments combined with RLRL therapy or involving red light

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

flicker rather than continuous administration. **Search Strategy** A comprehensive search of the peer-reviewed literature was conducted across seven databases, including PubMed, Embase, Web of Science, Cochrane Library, Scopus, the Chinese databases China National Knowledge Infrastructure and VIP Information Database, from their dates of inception through 10 February 2024. We used a combination of key words related to myopia and RLRL therapy, imposing no language restrictions. To ensure thorough coverage, we also scrutinized relevant reviews and all references cited by eligible studies for additional pertinent publications. The full search strategy is detailed in **Table S1**. **Study Selection** Citations retrieved from electronic databases were compiled into an EndNote library by one author (Y.C.). After the removal of duplicates, two reviewers (Y.C., R.X.) independently screened titles and abstracts to assess initial eligibility. Reviewers then checked the full text for potentially eligible studies to determine their final inclusion or exclusion. The primary reason for exclusion was documented at the full text screening stage. Any discrepancies between reviewers were resolved through discussion or by consulting a third researcher if necessary (W.W.). Data Collection and Risk of Bias Assessment Data were extracted independently by two reviewers (Y.C., R.X.) and were entered into an Excel spreadsheet (version 2022, Microsoft Corporation, Redmond, USA). For each included study, the extracted information consisted of author's name, year of publication, study design, country or area, specification of the red light device (device name, manufacturer, wavelength and power), treatment regimen, sample size, follow-up duration, age, sex, baseline SER, baseline AL, safety outcomes, and participation completion rate. For the safety outcomes, we documented all safety data reported throughout the selected studies. Two reviewers (Y.C., S.Y.)

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

independently appraised articles for systematic bias using the Cochrane Risk of Bias Tool. 14 **Data Synthesis and Analysis** Given the heterogeneous reporting of safety outcomes among the included studies, it was not feasible to conduct a pooled meta-analysis. 15 Instead, we performed a risk-to-benefit analysis according to the model described by Bullimore to assess whether the potential benefits of reducing myopia progression of 1D with RLRL therapy outweigh the potential risks associated with the treatment. <sup>16</sup> The revised Bullimore's model is based on three assumptions: 1) Every patient undergoing myopia control will use RLRL for a 5-year treatment period. Since there's lack of long-term efficacy of RLRL therapy, the selection of five years facilitates the conservative estimation of the effect of controlling myopia progression within 1D as per previous review. <sup>17</sup> 2) Serious adverse events, if they occur, may happen at a mean age of 12 years during this five-year treatment period. 16 3) Based on the estimated mean life expectancy of 77 years in China (https://data.who.int), any adverse event resulting in immediate visual impairment will lead to visual impairment for a duration of 65 years. The annual incidence rate of vision loss was calculated using the number of children experiencing visual impairment from RLRL as the numerator and the estimated total number of patient-years in reported clinical RLRL studies with safety outcomes as the denominator. The absolute risk increase (ARI) of vision loss years was estimated by multiplying the annual incidence of vision loss per 10,000 patients by the assumed duration of visual impairment, which is 65 years. The number needed to harm (NNH) was then calculated as the reciprocal of ARI. This metric indicates the number of patients who need to be treated to induce one case of visual impairment. According to Bullimore's model, the benefit of preventing visual impairment from blinding myopic related complications by 1D was regardless of the treatment. The average duration of visual impairment that a patient is likely to experience over their lifetime at myopia ranging from -3D to -8D was estimated. <sup>16</sup> For instance, a patient

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

2.42

243

244

245

246

2.47

248

249

with -3D myopia is expected to experience an average of 4.42 years of visual impairment (mild visual impairment as US definition of 20/40) while a -4D person will experience 5.25 years of visual impairment. Thus, the benefit of slowing myopia progression by 1D is quantified by the difference in years of visual impairment, amounting to a prevention of 0.84 years of visual impairment if myopia control interventions in an individual potentially reaching -4D myopia result in achieving only -3D. The values of years of visual impairment prevented by 1D reduction ranges from 0.74 to 1.22 for -3D to -8D. The number needed to treat (NNT) was evaluated in Bullimore's model to prevent 1-year (NNT range, 0.82-1.38) and 5-year (NNT range, 4.11-6.75) visual impairment. <sup>16</sup> Furtherly, we calculated the NNH/NNT ratio for RLRL therapy in patients with myopia degrees ranging from -3D to -8D. Additionally, we conducted a systematic comparison of the incidence of side effects between RLRL therapy and other anti-myopia interventions. Our approach involved a systematic search of all eligible peer-reviewed RCTs that included myopic or premyopic participants younger than 18 years, had at least a one-year follow-up period, and investigated interventions including low-dose atropine, orthokeratology, other contact lenses, and spectacles. For spectacles, we included bifocal lens, progressive addition spectacles, aspherical lenslets and peripheral defocus spectacles as spectacles designed for myopia reduction since their incidence rates of adverse events were similar. Adverse events of other interventions were counted as the number of events reported in published RCTs. The crude incidence of adverse events was computed per 100 patient-years of intervention, with 95% confidence intervals (CIs) calculated using the Wilson method. 18, 19 A two-sided p value < 0.05 was defined as statistically significant. All data analyses were performed using Stata (version 17.0, StataCorp, College Station, Texas, USA). Results **Study Selection** Of the 689 references retrieved, 39 full-text articles (5.66%) were reviewed, and 20

251

252

253

254

255

256

257

258

2.59

260

261

262

263

264

265

266

267

268

269

270

2.71

272

273

2.74

275

276

277

278

279

studies (2.90%) were identified as eligible for systematic review (**Figure 1**). The primary reason for exclusion during the full-text review process was the absence of reported safety outcomes (n=14, 73.7%).<sup>7, 20-32</sup> **Characteristics of Included Studies** The 20 studies comprised eleven RCTs, 8, 10, 11, 33-40 four non-randomized controlled trials, 41-44 one post-trial study, 9 one single-arm study, 45 one retrospective study 46 and two case reports of identical patient. <sup>47, 48</sup> Fifteen studies evaluated the safety and efficacy of RLRL therapy compared to controls, eleven with single-vision spectacles (SVS), 8, 10, 33, 35-37, 39-43 one with a sham device, 11 one with 0.01% atropine, 34 and one with orthokeratology, SVS, and combination treatment of orthokeratology and RLRL.<sup>44</sup> One study compared the safety and efficacy between RLRL devices with different powers and SVS.<sup>38</sup> Two case reports described the identical individual case with different details; 47, 48 thus we comprehensively reviewed the two reports but only included as one participant in the systematic review. These studies included a total of 2,380 participants aged 3-18 years presenting at baseline with myopia (cycloplegic SER -0.50 to -9.00D) or premyopia (cycloplegic SER -0.50 to +0.75D), among them 1,436 subjects undergoing RLRL therapy. The median follow-up duration was 9 months, with an interquartile range of 6-12 months, and a longest follow-up period of 24 months. All studies reported a participant completion rate of over 50%, were conducted in China, and published between 2021 and 2024. (**Table 1**). The risk of bias assessment is shown in **Figure 2**. The specifications of RLRL therapy and treatment regimens across the included studies are summarized in **Table S2**. Four types of RLRL devices were utilized, including Eyerising (Jiangsu, China; n=14 studies; 650±10 nm, 2.00±0.50 mW). 8-11, 33, <sup>34, 40-42, 44-48</sup> LD-A (Jilin, China; n=2 studies; 635 nm, 0.35±0.02 mW), <sup>35, 37</sup> YF020A (Hunan, China; n=3 studies; 650 nm, no specified power), 36, 39, 43 and sky-n1201 (Beijing, China; n=1 study; 650 nm, with variable outputs of 0.37±0.02 mW, 0.60±0.2 mW, and 1.20 mW). <sup>38</sup> All studies adhered to a uniform daily RLRL treatment protocol,

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

consisting of two daily 3-minute sessions, with a minimum interval of 4 hours between sessions. Six studies implemented a 5-day per week regimen,  $^{8\text{-}10,\,41,\,43,\,46}$ while the remaining 14 studies provided treatment 7 days per week. 11, 33-40, 42, 44, 45, 47, 48 Safety Profiles of RLRL Therapy **Table 2** presents the safety outcomes reported among participants undergoing RLRL therapy. In these studies, visual function was assessed using best-corrected visual acuity (BCVA) or multifocal electroretinogram, while ocular structures were evaluated with optical coherence tomography (OCT), fundus photography, or slit-lamp microscopy. Among 529 children assessed for visual function, 528 (99.8%) either maintained a BCVA of ≥20/25 or experienced no decline at follow-up visits compared to baseline. OCT identified no structural damage in 624 (99.8%) of the 625 participants with such data. Two case reports described the same twelve-year-old girl who experienced a two-line decline in binocular BCVA after five months of RLRL therapy. 47, 48 The child was highly myopic prior to initiating RLRL, with SER of -6.75D in the right eye and -6.25D in the left eye, and BCVA of 20/25 at the point of initiation. Due to repeated inflammation from orthokeratology, the subject had been switched to RLRL for managing myopia. After three months of RLRL treatment, the BCVA improved to 20/20. After five months for RLRL treatment, the child showed the binocular BCVA decrease from 20/20 to 20/30 with prolonged afterimages occasionally exceeding 8 minutes. Multifocal electroretinogram indicated moderately and mildly decreased response in the macula and paramacular respectively. OCT images showed bilateral disruption of the foveal ellipsoid zone and discontinuity of the interdigitation zone. Fundus photographs revealed bilaterally darkened foveae with a hypoautofluorescent plaque in autofluorescence images. The bilateral outer retinal damage showed partial recovery, with an improvement in binocular BCVA to 20/25, three months after discontinuation of RLRL therapy. Complete recovery of bilateral outer retinal damage was observed four months after discontinuing RLRL therapy.

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

Nineteen studies reported on ocular adverse events. In one study with 20 participants treated with RLRL, afterimages lasting a mean of 3.2±1.2 minutes were documented without any objective ocular abnormalities.<sup>37</sup> One trial reported afterimage as the most common phenomenon post light therapy, which can be alleviated by a short period of eye-closing and rest. <sup>41</sup> Another study demonstrated no afterimages longer than 6 minutes after 1-year RLRL treatment within 126 premyopic children. <sup>10</sup> One individual experienced dizziness following the red-light therapy; however, this symptom resolved within a few minutes and persisted during the immediate post-treatment period for only a few days.<sup>34</sup> Aside from the aforementioned case report, <sup>47, 48</sup> no other included participants experienced vision loss of ≥2 lines, scotoma or treatment-related adverse events post-therapy. **Risk-to-benefit Analysis** The sole event of temporary vision loss described in the case reports is considered as the numerator, <sup>47, 48</sup> and the denominator is a conservative estimate of the total number of participants in reported clinical RLRL studies with safety outcomes. The annual incidence of vision loss from RLRL therapy was estimated as 8.77 per 10,000 patient-years. **Table 3** shows the NNH and NNH/NNT estimates for 1 year and 5 years visual impairment associated with RLRL based on Bullimore's model. A total of 17.5 individuals have to implement RLRL therapy for 5 years to result in 1-year of visual impairment, while 87.7 patients have to use it to result in 5-year of visual impairment. From Bullimore's assessment, controlling myopia by 1D prevents between 0.74 and 1.22 years of visual impairment due to myopic complications across myopia levels of -3D to -8D. 16 This benefit outweighs the risk of visual impairment years from RLRL treatment, which is 570 per 10,000 patients, or 0.057 year per patient. On the other hand, the NNH outweighs the NNT by a ratio of 12.7-21.4 for a person with -3D to -8D myopia treated with RLRL therapy.

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

**Comparison with Other Interventions** We further compared the incidence rates of ocular adverse events between RLRL and other myopia interventions. The characteristics and adverse events of other treatments reported in RCTs lasting at least 1 year are displayed in **Table S3**. The side effect incidence of RLRL therapy is 0.088 per 100 patient-years (95% confidence interval [CI], 0.02-0.50), which is comparable to spectacles designed for myopia reduction (0.22 per 100 patient-years; 95% CI, 0.09-0.51; P=0.385), 49-59 and significantly lower than for low-dose atropine (7.32 per 100 patient-years; 95% CI, 6.65-8.05; P<0.001), 60-78 orthokeratology (20.6 per 100 patient-years; 95% CI, 16.7-25.0; P<0.001)<sup>77, 79-84</sup> and other anti-myopia contact lens (19.3 per 100 patient-years; 95% CI, 17.6-21.1; P<0.001)<sup>85-90</sup> (**Table 4**). **Discussion** The results of the systematic review indicated that no visual function loss or ocular structural change with irreversible damage was identified with RLRL therapy. An afterimage was the most common ocular symptom following treatment, with a resolution time of less than 6 minutes reported in two clinical trials. This phenomenon, induced by prior adaptation to a visual stimulus, is believed to be due to the natural bleaching of photochemical pigments or neural adaptation in the retina. Participants with an afterimage duration exceeding 6 minutes were considered clinically too sensitive to the light stimulus. 10,91 Among dozens of published studies, only two reported on a single case of a reversible decline in visual function and discontinuity of the foveal ellipsoid and interdigitation zones in an identical girl, with complete recovery after four months of treatment cessation. A risk-to-benefit analysis emphasized that the benefit of reducing visual impairment outweighed the potential risks associated with RLRL treatment. The incidence rate of side effects from RLRL therapy was comparable to that of spectacles wearing, and was lower than that of other therapies.

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

Of note, two case reports, both describing on complications of the same child following RLRL therapy offers valuable clinical data and serves as a reference point for RLRL's clinical application. <sup>47, 48</sup> Given the rarity of this adverse event, it might be secondary to specific individual differences, where the patient may be especially responsive to light therapy. Such individual variability may render the retina more sensitive to light and prone to phototoxicity. It is important to note that the patient was highly myopic, a condition that often involves inherent issues with the retinal structure of the fundus. From the addition information provided by the authors of one case report, 48 this child experienced significant myopia regression (cycloplegic SER from -6.75D at baseline to -4.50D after 1 month in the right eye; from -6.25D at baseline to -4.50D after 1 month in the left eye) following RLRL treatment. The dark choroid shown in the OCT image post RLRL has been suggested in a non peer-reviewed letter to the editor regarding the case written by experts in inherited retinal disease to represent Stargardt's disease (https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2805391). Although the incidence of such adverse events is extremely low, identifying such super-responders to RLRL therapy is still important. From this case, possible characteristics of super-responders include a significant treatment effect, a marked SER regression or AL shortening and an afterimage duration exceeding 6 minutes in response to light exposure. It is crucial for clinicians and parents to closely monitor subjects with these characteristics, as any decrease in visual acuity while wearing glasses may suggest the development of such complications, which can then be further detected and characterized through OCT examination. Importantly, these complications are reversible as after stopping treatment for 4 months, the visual function and ocular structures changes returned to normal. Meticulous supervision is thus necessary throughout the treatment process to ensure safe implementation of RLRL. Appropriate actions include documentation of the retina through fundus photography and OCT before starting treatment and at each routine examination, tracking visual acuity, and recording the duration of any afterimages.<sup>92</sup>

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

A comprehensive risk-to-benefit assessment of myopia treatments should consider various factors, including the intervention effectiveness in slowing myopia progression, the risk of myopia-related visual impairment, the degree of myopia treated, and the specific risks associated with each intervention. From this risk-to-benefit analysis, the risk of vision loss associated with RLRL treatment is seen to be counterbalanced by its benefits in preventing myopia-related visual impairment with a NNH/NNT ratio of 12.7 to 21.4. Previous studies have reported a NNH/NNT ratio ranging from 5.43 for -3D to 9.15 for -8D for overnight contact lens wearing. 16, Additionally, nearly all interventions for myopia control are associated with some side effects and complications. Our systematic review summarized RCTs with at least one year of follow-up reporting the incidence of side effects from available anti-myopia interventions. Our findings indicate that the incidence of adverse events associated with orthokeratology is 20.6 per 100 patient-years, while it was 19.3 per 100 patient-years for other contact lens. Complications linked to contact lens usage included ocular noninfectious inflammatory events and sight-threatening microbial keratitis. 90, 94-96 A retrospective study authorized and approved by the US FDA estimated the incidence of microbial keratitis from orthokeratology in children to be 14 per 10,000 patient-years (95% CI, 1.7-50.4 per 10,000 patient-years). 97 Atropine, even at low concentrations of 0.01%, may lead to pupil dilation and loss of accommodation, with photophobia, reduced near vision, and allergic conjunctivitis being commonly reported ocular side effects. 98,99 Spectacles in comparison are a more well-tolerated method for correcting and controlling myopia; however, they are associated with a low risk of falls and bicycle collisions. 51, 100 In this review, RLRL therapy had a comparable incidence of side effects with spectacles. This systematic review provides the first comprehensive evidence on the safety profile and the risk-to-benefit ratio of RLRL therapy for myopia control. However, the results

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

should be interpreted within the context of several limitations. Firstly, most studies lasted for 12 months, with only 11 children undergoing 24-month treatment in one post-trial study included thereby limiting long-term evidence. There is a need for further large-scale studies to thoroughly assess the long-term safety of RLRL therapy in children and adolescents. Secondly, visual function in the included studies was primarily evaluated using visual acuity, which could be influenced by subjective factors. Objective assessments, such as multifocal electroretinography or microperimetry, are necessary to provide more comprehensive safety evidence for RLRL therapy. Thirdly, the methodology for reporting adverse events varied widely across studies. Some studies documented the number of patients experiencing side effects, whereas others detailed the number of adverse events. Fourthly, the accuracy of Bullimore's model is dependent on the validity of its assumptions. <sup>16</sup> It presumses that the risk of vision loss from RLRL therapy is independent of refractive error. The model also assumes a fixed treatment effect with myopia control. Fifthly, quality appraisal was employed exclusively for the included RCTs, as the Cochrane Risk of Bias Tool is not designed for use with non-randomized controlled trial, post-trial study, retrospective study, single-arm study or case report. Finally, eleven of the twenty studies were RCTs, which were conducted under strict surveillance. Such studies may not accurately reflect real-world vision care, therefore more real-world studies are needed to better understand long-term safety of RLRL in a greater variety of settings. Conclusion In conclusion, no irreversible visual function loss or ocular structural damage associated with RLRL therapy was identified in this review. Meticulous supervision is crucial throughout the entire treatment process by clinicians and parents, including documenting the status of retina through fundus photography and OCT before initiating RLRL therapy and at each routine examination, as well as tracking visual acuity and the duration of any afterimages at home. Screening for and early identification of rare super-responders is also important to avoid potential light injury. Future larger and longer-term real-world studies are needed to better understand the

460 long-term safety of RLRL. 461 462 Acknowledgment 463 The authors thank the Hainan Province Clinical Medical Center, the National Natural 464 Science Foundation of China (82371086) for their support. 465 466 **Author Contributions:** 467 Prof. Wang had full access to all the data in the study and took responsibility for the 468 integrity of the data and the accuracy of the data analysis. 469 Study concept and design: Chen, Congdon, Wang. 470 Data collection: Chen, Chen, Xiong, Yang, Wang. 471 Analysis and interpretation of data: Chen, Wang. 472 Drafting of the manuscript: Chen, Congdon, Wang. 473 Critical revision of the manuscript for important intellectual content: All authors. 474 Statistical analysis: Chen, Wang. 475 Obtained funding: Wang. 476 Administrative, technical, or material support: Congdon, Wang. 477 Overall supervision: Wang.

- 478 **References:**
- 1. Holden BA, Fricke TR, Wilson DA, et al. Global Prevalence of Myopia and High
- 480 Myopia and Temporal Trends from 2000 through 2050. Ophthalmology
- 481 2016;123(5):1036-42.
- 482 2. Bullimore MA, Brennan NA. Myopia Control: Why Each Diopter Matters.
- 483 Optom Vis Sci 2019;96(6):463-5.
- 484 3. Ikuno Y. Overview of the Complications of High Myopia. Retina
- 485 2017;37(12):2347-51.
- 486 4. Mitchell P, Hourihan F, Sandbach J, Jin Wang J. The relationship between
- 487 glaucoma and myopia. Ophthalmology 1999;106(10):2010-5.
- 5. Sankaridurg P, Berntsen DA, Bullimore MA, et al. IMI 2023 Digest. Invest
- 489 Ophthalmol Vis Sci 2023;64(6):7.
- 490 6. ANSI. American National Standard for Safe Use of Lasers (ANSI Z80.36). The
- 491 Laser Institute of America. ANSI Z80.36-2021.
- 492 7. Xiong R, Zhu Z, Jiang Y, et al. Longitudinal Changes and Predictive Value of
- 493 Choroidal Thickness for Myopia Control after Repeated Low-Level Red-Light
- 494 Therapy. Ophthalmology 2023;130(3):286-96.
- 8. Jiang Y, Zhu Z, Tan X, et al. Effect of Repeated Low-Level Red-Light Therapy
- for Myopia Control in Children: A Multicenter Randomized Controlled Trial.
- 497 Ophthalmology 2022;129(5):509-19.
- 498 9. Xiong R, Zhu Z, Jiang Y, et al. Sustained and rebound effect of repeated low-level
- red-light therapy on myopia control: A 2-year post-trial follow-up study. Clin Exp
- 500 Ophthalmol 2022;50(9):1013-24.
- 501 10. He X, Wang J, Zhu Z, et al. Effect of Repeated Low-level Red Light on Myopia
- 502 Prevention Among Children in China With Premyopia: A Randomized Clinical Trial.
- 503 JAMA Netw Open 2023;6(4):e239612.
- 11. Dong J, Zhu Z, Xu H, He M. Myopia Control Effect of Repeated Low-Level
- Red-Light Therapy in Chinese Children: A Randomized, Double-Blind, Controlled
- 506 Clinical Trial. Ophthalmology 2023;130(2):198-204.
- 507 12. Tang J, Liao Y, Yan N, et al. Efficacy of Repeated Low-Level Red-Light Therapy

- for Slowing the Progression of Childhood Myopia: A Systematic Review and
- 509 Meta-analysis. Am J Ophthalmol 2023;252:153-63.
- 13. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an
- updated guideline for reporting systematic reviews. BMJ 2021;372:n71.
- 512 14. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool
- for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
- 514 15. Gilbert CE, Lepvrier-Chomette N. Gender Inequalities in Surgery for Bilateral
- Cataract among Children in Low-Income Countries: A Systematic Review.
- 516 Ophthalmology 2016;123(6):1245-51.
- 517 16. Bullimore MA, Ritchey ER, Shah S, et al. The Risks and Benefits of Myopia
- 518 Control. Ophthalmology 2021;128(11):1561-79.
- 17. Brennan NA, Toubouti YM, Cheng X, Bullimore MA. Efficacy in myopia control.
- 520 Prog Retin Eye Res 2021;83:100923.
- 18. Agresti A, Coull B. Approximate Is Better than "Exact" for Interval Estimation of
- Binomial Proportions. The American Statistician 1998;52(2):119-26.
- 523 19. Wilson E. Probable Inference, the Law of Succession, and Statistical Inference.
- Journal of the American Statistical Association 1927;22(158):209-12.
- 525 20. Jia S, Zhang N, Liu D, et al. Comparative Analysis of the Efficacy of
- Low-Intensity Single-Wavelength Red Light Instrument and Acupuncture Therapy for
- 527 Preventing and Controlling Myopia in Adolescent Children. Advances in Clinical
- 528 Medicine 2022;12(12).
- 529 21. Jin X. Observation of the efficacy of repeated low-intensity red light irradiation
- on the prevention and control of myopia in children and adolescents. Chinese Science
- and Technology Journal Database Medicine 2023(7).
- 532 22. Lai W, Jia Y, Zhang Y, et al. Efficacy of low level red light in young children
- with high myopia. Recent Advances in Ophthalmology 2022;42(09):727-30.
- 23. Li E, Wang J, Huang H, et al. Efficacy of low-intensity red light on controlling
- the refractive growth of myopia in adolescents. Chinese Science and Technology
- Journals Database Medicine and Health 2022(10).
- 537 24. Ma G, Yan S, Zhao G, Wang K. Comparison of the effects of repeated

- low-intensity red light irradiation and 0.01% atropine eye drops on the prevention and
- control of myopia in children and adolescents. Chinese Journal of Eye Trauma and
- Occupational Ophthalmology 2023;45(8).
- 541 25. Qiu K, Zhou L. Myopic Axial Length Change with Low-Intensity Laser Light
- Therapy. Glass Enamel & Ophthalmic Optics 2021;49(09):17-22.
- 543 26. Wang W, Jiang Y, Zhu Z, et al. Axial Shortening in Myopic Children after
- Repeated Low-Level Red-Light Therapy: Post Hoc Analysis of a Randomized Trial.
- 545 Ophthalmol Ther 2023;12(2):1223-37.
- 546 27. Xiong F, Mao T, Liao H, et al. Orthokeratology and Low-Intensity Laser Therapy
- for Slowing the Progression of Myopia in Children. Biomed Res Int
- 548 2021;2021:8915867.
- 549 28. Xuan M, Zhu Z, Jiang Y, et al. Longitudinal Changes in Choroidal Structure
- Following Repeated Low-Level Red-Light Therapy for Myopia Control: Secondary
- Analysis of a Randomized Controlled Trial. Asia Pac J Ophthalmol (Phila)
- 552 2023;12(4):377-83.
- 553 29. Yang W, Lin F, Li M, et al. Immediate Effect in the Retina and Choroid after 650
- nm Low-Level Red Light Therapy in Children. Ophthalmic Res 2023;66(1):312-8.
- 30. Zhou L, Qiu K, Tong L. The Analysis of Clinical Trial of Slowing the Progression
- of Myopiain Children with Low Red Laser. Glass Enamel & Ophthalmic Optics
- 557 2022;50(1).
- 558 31. Zhou L, Xing C, Qiang W, et al. Low-intensity, long-wavelength red light slows
- the progression of myopia in children: an Eastern China-based cohort. Ophthalmic
- 560 Physiol Opt 2022;42(2):335-44.
- 561 32. Zhu X. Analysis of the therapeutic effect of low energy red light on myopia in
- children and adolescents. Chinese Science and Technology Journal Database
- 563 Medicine 2023(7).
- 33. Yan Y, Xue W, Zhao Y, et al. Effect of 650 nm semiconductor laser on juvenile
- myopia control. Journal of Clinical Ophthalmology 2021;29(02):132-7.
- 566 34. Chen Y, Xiong R, Chen X, et al. Efficacy Comparison of Repeated Low-Level
- 567 Red Light and Low-Dose Atropine for Myopia Control: A Randomized Controlled

- 568 Trial. Transl Vis Sci Technol 2022;11(10):33.
- 569 35. Chen H, Wang W, Liao Y, et al. Low-intensity red-light therapy in slowing
- myopic progression and the rebound effect after its cessation in Chinese children: a
- randomized controlled trial. Graefe's Archive for Clinical and Experimental
- 572 Ophthalmology 2023;261(2):575-84.
- 36. Tian L, Cao K, Ma DL, et al. Investigation of the Efficacy and Safety of 650 nm
- 574 Low-Level Red Light for Myopia Control in Children: A Randomized Controlled
- 575 Trial. Ophthalmol Ther 2022;11(6):2259-70.
- 576 37. Zhou L, Tong L, Li Y, et al. Photobiomodulation therapy retarded axial length
- 577 growth in children with myopia: evidence from a 12-month randomized controlled
- trial evidence. Sci Rep 2023;13(1):3321.
- 38. Zhou W, Liao Y, Wang W, et al. Efficacy of Different Powers of Low-Level Red
- Light in Children for Myopia Control. Ophthalmology 2024;131(1):48-57.
- 581 39. Tian L, Cao K, Ma DL, et al. Six-month repeated irradiation of 650 nm low-level
- red light reduces the risk of myopia in children: a randomized controlled trial. Int
- 583 Ophthalmol 2023;43(10):3549-58.
- 584 40. Liu Z, Sun Z, Du B, et al. The Effects of Repeated Low-Level Red-Light Therapy
- on the Structure and Vasculature of the Choroid and Retina in Children with
- 586 Premyopia. Ophthalmol Ther 2024;13(3):739-59.
- 41. Lin ZH, Tao ZY, Kang ZF, Deng HW. A Study on the Effectiveness of 650-nm
- 588 Red-Light Feeding Instruments in the Control of Myopia. Ophthalmic Research
- 589 2023;66(1):664-71.
- 590 42. Zhao C, Ni Y, Zeng J. Effect of red-light therapy on retinal and choroidal blood
- 591 perfusion in myopic children. Ophthalmic Physiol Opt 2023;43(6):1427-37.
- 592 43. Xiong Y, Hu J, Gu C, Tang J. Influence of low ☐ intensity red light therapy on
- 593 diopter changes , axial length and tear film rupture time in adolescent myopia patients.
- Journal of North Sichuan Medical College 2024;39(01):100-3.
- 595 44. Zhang L, Guo Y, Chen J, et al. Clinical effect of 650-nm low-level red light in
- 596 conjunction with orthokeratology in myopia control. Journal of Otolaryngology and

- 597 Ophthalmology of Shandong University 2024:1-8.
- 598 45. Liu L, Wang Y, Liu F, et al. Effects of repeated low-level red-light therapy on
- macular retinal thickness and microvascular system in children with myopia.
- Photodiagnosis Photodyn Ther 2024;45:103938.
- 46. Wang W, Jiang Y, Zhu Z, et al. Clinically Significant Axial Shortening in Myopic
- 602 Children After Repeated Low-Level Red Light Therapy: A Retrospective Multicenter
- Analysis. Ophthalmol Ther 2023;12(2):999-1011.
- 47. Liu H, Yang Y, Guo J, et al. Retinal Damage After Repeated Low-level Red-Light
- Laser Exposure. JAMA Ophthalmology 2023.
- 48. Tian Y, Xiao Z. Recovery of retinal structural damage after repeated low-intensity
- red light therapy for high myopia: a case report. Chinese Journal of Experimental
- 608 Ophthalmology 2023;41(9):853-5.
- 609 49. Gwiazda J, Hyman L, Hussein M, et al. A randomized clinical trial of progressive
- addition lenses versus single vision lenses on the progression of myopia in children.
- 611 Invest Ophthalmol Vis Sci 2003;44(4):1492-500.
- 612 50. Cheng D, Schmid KL, Woo GC, Drobe B. Randomized Trial of Effect of Bifocal
- and Prismatic Bifocal Spectacles on Myopic Progression Two-Year Results. Arch
- 614 Ophthalmol 2010 128(1):12-9.
- 51. Sankaridurg P, Donovan L, Varnas S, et al. Spectacle lenses designed to reduce
- progression of myopia: 12-month results. Optom Vis Sci 2010;87(9):631-41.
- 617 52. Correction of Myopia Evaluation Trial 2 Study Group for the Pediatric Eye
- 618 Disease Investigator G. Progressive-addition lenses versus single-vision lenses for
- 619 slowing progression of myopia in children with high accommodative lag and near
- 620 esophoria. Invest Ophthalmol Vis Sci 2011;52(5):2749-57.
- 53. Hasebe S, Jun J, Varnas S. Myopia Control with Positively-Aspherized
- Progressive 2 Addition Lenses- A Two-year, Multicenter, Randomized,
- 623 Controlled Trial. Invest Ophthalmol Vis Sci 2014
- 54. Kanda H, Oshika T, Hiraoka T, et al. Effect of spectacle lenses designed to reduce
- 625 relative peripheral hyperopia on myopia progression in Japanese children: a 2-year
- multicenter randomized controlled trial. Jpn J Ophthalmol 2018;62(5):537-43.

- 55. Lam CSY, Tang WC, Tse DY, et al. Defocus Incorporated Multiple Segments
- 628 (DIMS) spectacle lenses slow myopia progression: a 2-year randomised clinical trial.
- 629 Br J Ophthalmol 2020;104(3):363-8.
- 630 56. Bao J, Yang A, Huang Y, et al. One-year myopia control efficacy of spectacle
- lenses with aspherical lenslets. Br J Ophthalmol 2022;106(8):1171-6.
- 632 57. Bao J, Huang Y, Li X, et al. Spectacle Lenses With Aspherical Lenslets for
- 633 Myopia Control vs Single-Vision Spectacle Lenses: A Randomized Clinical Trial.
- 634 JAMA Ophthalmol 2022;140(5):472-8.
- 58. Liu X, Wang P, Xie Z, et al. One-year myopia control efficacy of cylindrical
- annular refractive element spectacle lenses. Acta Ophthalmol 2023;101(6):651-7.
- 637 59. Rappon J, Chung C, Young G, et al. Control of myopia using diffusion optics
- spectacle lenses: 12-month results of a randomised controlled, efficacy and safety
- 639 study (CYPRESS). Br J Ophthalmol 2023;107(11):1709-15.
- 640 60. Yen M, Liu J, Kao S, Shiao C. Comparison of the effect of atropine and
- 641 cyclopentolate on myopia. Ann Ophthalmol 1989;21(5):180-7.
- 642 61. Shih YF, Chen CH, Chou AC, et al. Effects of different concentrations of atropine
- on controlling myopia in myopic children. JOURNAL OF OCULAR
- PHARMACOLOGY AND THERAPEUTICS 1999;15(1):85-90.
- 645 62. Chua WH, Balakrishnan V, Chan YH, et al. Atropine for the treatment of
- 646 childhood myopia. Ophthalmology 2006;113(12):2285-91.
- 63. Chia A, Chua WH, Cheung YB, et al. Atropine for the treatment of childhood
- myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the
- 649 Treatment of Myopia 2). Ophthalmology 2012;119(2):347-54.
- 650 64. Yi S, Huang Y, Yu S, et al. Therapeutic effect of atropine 1% in children with low
- myopia. J AAPOS 2016;20(4):379.
- 652 65. Wang YR, Bian HL, Wang Q. Atropine 0.5% eyedrops for the treatment of
- children with low myopia: A randomized controlled trial. Medicine (Baltimore)
- 654 2017;96(27):e7371.
- 655 66. Yam JC, Jiang Y, Tang SM, et al. Low-Concentration Atropine for Myopia
- 656 Progression (LAMP) Study: A Randomized, Double-Blinded, Placebo-Controlled

- Trial of 0.05%, 0.025%, and 0.01% Atropine Eye Drops in Myopia Control.
- Ophthalmology 2019;126(1):113-24.
- 659 67. Wei S, Li SM, An W, et al. Safety and Efficacy of Low-Dose Atropine Eyedrops
- 660 for the Treatment of Myopia Progression in Chinese Children: A Randomized Clinical
- Trial. JAMA Ophthalmol 2020;138(11):1178-84.
- 662 68. Yam JC, Li FF, Zhang X, et al. Two-Year Clinical Trial of the Low-Concentration
- Atropine for Myopia Progression (LAMP) Study: Phase 2 Report. Ophthalmology
- 664 2020;127(7):910-9.
- 665 69. Cui C, Li X, Lyu Y, et al. Safety and efficacy of 0.02% and 0.01% atropine on
- controlling myopia progression: a 2-year clinical trial. Sci Rep 2021;11(1):22267.
- 70. Hieda O, Hiraoka T, Fujikado T, et al. Efficacy and safety of 0.01% atropine for
- 668 prevention of childhood myopia in a 2-year randomized placebo-controlled study. Jpn
- 669 J Ophthalmol 2021;65(3):315-25.
- 670 71. Saxena R, Dhiman R, Gupta V, et al. Atropine for the Treatment of Childhood
- Myopia in India: Multicentric Randomized Trial. Ophthalmology
- 672 2021;128(9):1367-9.
- 673 72. Lee SS, Lingham G, Blaszkowska M, et al. Low-concentration atropine eyedrops
- 674 for myopia control in a multi-racial cohort of Australian children: A randomised
- 675 clinical trial. Clin Exp Ophthalmol 2022;50(9):1001-12.
- 73. Yam JC, Zhang XJ, Zhang Y, et al. Three-Year Clinical Trial of
- 677 Low-Concentration Atropine for Myopia Progression (LAMP) Study: Continued
- 678 Versus Washout: Phase 3 Report. Ophthalmology 2022;129(3):308-21.
- 679 74. Chia A, Ngo C, Choudry N, et al. Atropine Ophthalmic Solution to Reduce
- Myopia Progression in Pediatric Subjects: The Randomized, Double-Blind
- Multicenter Phase II APPLE Study. Asia Pac J Ophthalmol (Phila) 2023;12(4):370-6.
- 75. Hansen NC, Hvid-Hansen A, Moller F, et al. Safety and efficacy of 0.01% and 0.1%
- low-dose atropine eye drop regimens for reduction of myopia progression in Danish
- children: a randomized clinical trial examining one-year effect and safety. BMC
- 685 Ophthalmol 2023;23(1):438.
- 686 76. Moriche-Carretero M, Revilla-Amores R, Gutierrez-Blanco A, et al. Five-year


- results of atropine 0.01% efficacy in the myopia control in a European population. Br
- 688 J Ophthalmol 2023.
- 689 77. Xu S, Li Z, Zhao W, et al. Effect of atropine, orthokeratology and combined
- treatments for myopia control: a 2-year stratified randomised clinical trial. Br J
- 691 Ophthalmol 2023;107(12):1812-7.
- 692 78. Yam JC, Zhang XJ, Zhang Y, et al. Effect of Low-Concentration Atropine
- 693 Eyedrops vs Placebo on Myopia Incidence in Children: The LAMP2 Randomized
- 694 Clinical Trial. JAMA 2023;329(6):472-81.
- 79. Cho P, Cheung SW. Retardation of myopia in Orthokeratology (ROMIO) study: a
- 696 2-year randomized clinical trial. Invest Ophthalmol Vis Sci 2012;53(11):7077-85.
- 80. Charm J, Cho P. High Myopia–Partial Reduction Ortho-k A 2-Year Randomized
- 698 Study. Optom Vis Sci 2013.
- 81. Kinoshita N, Konno Y, Hamada N, et al. Efficacy of combined orthokeratology
- and 0.01% atropine solution for slowing axial elongation in children with myopia: a
- 701 2-year randomised trial. Sci Rep 2020;10(1):12750.
- 702 82. Tan Q, Ng AL, Choy BN, et al. One-year results of 0.01% atropine with
- orthokeratology (AOK) study: a randomised clinical trial. Ophthalmic Physiol Opt
- 704 2020;40(5):557-66.
- 705 83. Guo B, Cheung SW, Kojima R, Cho P. One-year results of the Variation of
- 706 Orthokeratology Lens Treatment Zone (VOLTZ) Study: a prospective randomised
- 707 clinical trial. Ophthalmic Physiol Opt 2021;41(4):702-14.
- 708 84. Jakobsen TM, Moller F. Control of myopia using orthokeratology lenses in
- 709 Scandinavian children aged 6 to 12 years. Eighteen-month data from the Danish
- 710 Randomized Study: Clinical study Of Near-sightedness; TReatment with
- 711 Orthokeratology Lenses (CONTROL study). Acta Ophthalmol 2022;100(2):175-82.
- 712 85. Walline JJ, Jones L, Mutti DO, Zadnik K. A randomized trial of the effects of
- rigid contact lenses on myopia progression. Arch Ophthalmol 2004
- 714 86. Cheng X, Xu J, Chehab K, et al. Soft Contact Lenses with Positive Spherical
- Aberration for Myopia Control. Optom Vis Sci 2016;93(4):353-66.
- 716 87. Chamberlain P, Peixoto-de-Matos SC, Logan NS, et al. A 3-year Randomized

- 717 Clinical Trial of MiSight Lenses for Myopia Control. Optom Vis Sci
- 718 2019;96(8):556-67.
- 719 88. Walline JJ, Walker MK, Mutti DO, et al. Effect of High Add Power, Medium Add
- Power, or Single-Vision Contact Lenses on Myopia Progression in Children: The
- 721 BLINK Randomized Clinical Trial. JAMA 2020;324(6):571-80.
- 722 89. Garcia-Del Valle AM, Blazquez V, Gros-Otero J, et al. Efficacy and safety of a
- soft contact lens to control myopia progression. Clin Exp Optom 2021;104(1):14-21.
- 724 90. Gaume Giannoni A, Robich M, Berntsen DA, et al. Ocular and Nonocular
- Adverse Events during 3 Years of Soft Contact Lens Wear in Children. Optom Vis Sci
- 726 2022;99(6):505-12.
- 727 91. Shimojo S, Kamitani Y, Nishida S. Afterimage of perceptually filled-in surface.
- 728 Science 2001;293(5535):1677-80.
- 729 92. Expert workgroup of expert consensus on repeated low-level red-light as an
- 730 alternative treatment for childhood myopia. Expert consensus on repeated low-level
- red-light as an alternative treatment for childhood myopia (2022). Chinese Journal of
- 732 Experimental Ophthalmology 2022;40(7):599-603.
- 733 93. Stapleton F, Keay L, Edwards K, et al. The incidence of contact lens-related
- microbial keratitis in Australia. Ophthalmology 2008;115(10):1655-62.
- 735 94. Cheng X, Brennan NA, Toubouti Y, Greenaway NL. Safety of soft contact lenses
- 736 in children: retrospective review of six randomized controlled trials of myopia control.
- 737 Acta Ophthalmol 2020;98(3):e346-e51.
- 738 95. Stapleton F. Contact lens related corneal infection in Australia. Clinical and
- 739 Experimental Optometry 2021;103(4):408-17.
- 740 96. Szczotka-Flynn LB, Shovlin JP, Schnider CM, et al. American Academy of
- Optometry Microbial Keratitis Think Tank. Optom Vis Sci 2021;98(3):182-98.
- 97. Bullimore MA, Sinnott LT, Jones-Jordan LA. The risk of microbial keratitis with
- overnight corneal reshaping lenses. Optom Vis Sci 2013;90(9):937-44.
- 744 98. Ha A, Kim SJ, Shim SR, et al. Efficacy and Safety of 8 Atropine Concentrations
- for Myopia Control in Children: A Network Meta-Analysis. Ophthalmology
- 746 2022;129(3):322-33.

99. Gong Q, Janowski M, Luo M, et al. Efficacy and Adverse Effects of Atropine in
Childhood Myopia: A Meta-analysis. JAMA Ophthalmol 2017;135(6):624-30.
100. Zhang M, Congdon N, Li L, et al. Myopia, spectacle wear, and risk of bicycle
accidents among rural Chinese secondary school students: the Xichang Pediatric
Refractive Error Study report no. 7. Arch Ophthalmol 2009;127(6):776-83.

## Figure Legends

 **Figure 1.** Study selection outlined according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. RCT=randomized controlled trial.



## Figure 2. Risk of bias assessment by Cochrane Risk of Bias Tool of the included

## RCTs. RCT=randomized controlled trial.

761

762

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
Chen (a) et al 2022	+	•	•	+	+	+	•
Chen (b) et al 2022  Dong et al 2022	<b>+</b>	?	•	+ +	+	<b>+</b>	?
He et al 2023	<b>+</b>	<b>+</b>		•	+	•	•
Jiang et al 2021	+	+	•	+	+	•	•
Liu (a) et al 2024	+	?		+	+	?	?
Tian (a) et al 2023	•	?	-	+	+	?	•
Tian et al 2022	+	?		+	+	?	•
Yan et al 2021	+	?	•	+	+	+	•
Zhou (a) et al 2023	•	•		•	•	?	+
Zhou (b) et al 2023	+	?		+	+	?	+

**Table 1.** Characteristics of included studies.

No. of Patients	Treatment	Age (y)	Female (%)	Mean SER (D)	Mean AL	Completion
by Study					(mm)	Rate (%)
(Study Type)						
Jiang et al 2021 (RCT	7)8					
117	Intervention (RLRL)	8-13	62 (52.1)	-2.49 (0.92)	24.5 (0.67)	98.3
129	Control (SVS)	8-13	72 (49.7)	-2.67 (1.06)	24.6 (0.86)	89.0
Yan et al 2021 (RCT)	33					
60	Intervention (RLRL)	7-12	59 (49 2)	-2.52 (1.15)	24.2 (0.92)	100
60	Control (SVS)	7-12	58 (48.3)	-2.53 (1.15)	24.4 (0.79)	100
Xiong et al 2022 (post	t-trial follow-up study) <sup>9</sup>					
11	RLRL-RLRL	8-13	4 (36.4)	-1.77 (0.57)	24.9 (0.94)	-
10	SVS-RLRL	8-13	5 (50.0)	-2.57 (1.11)	24.8 (0.71)	-
52	RLRL-SVS	8-13	26 (50.0)	-2.50 (0.83)	24.5 (0.58)	-
41	SVS-SVS	8-13	26 (63.4)	-2.76 (1.15)	24.6 (0.94)	-
Dong et al 2022 (RCT	7)11					
56	Intervention (RLRL)	7-12	30 (53.6)	-3.13 (1.91)	24.7 (1.04)	94.6
55	Control (Sham device)	7-12	26 (46.4)	-2.82 (1.86)	24.6 (0.96)	98.2
Chen (a) et al 2022 (R	(CT) <sup>34</sup>					
30	Intervention (RLRL)	7-15	17 (54.8)	-2.60 (1.17)	24.5 (0.79)	96.8
30	Control (0.01% atropine)	7-15	14 (45.2)	-2.59 (1.24)	24.7 (0.98)	96.8

Chen (b) et al 2	.022 (RCT) <sup>35</sup>					
46	Intervention (RLRL)	6-13	19 (41.3)	-2.54 (1.04)	24.6 (0.97)	90.2
40	Control (SVS)	6-13	15 (37.5)	-2.29 (0.77)	24.6 (0.76)	78.4
Tian et al 2022	(RCT) <sup>36</sup>				,	
91	Intervention (RLRL)	6-12	55 (49.1)	-2.00 (0.33)	24.3 (0.92)	81.3
88	Control (SVS)	6-12	57 (50.9)	-2.00 (0.25)	24.2 (0.85)	78.6
He et al 2023 (I	RCT) <sup>10</sup>					
126	Intervention (RLRL)	6-11	68 (48.9)	0.14 (0.30)	23.4 (0.68)	90.7
122	Control (SVS)	6-11	71 (51.1)	0.16 (0.28)	23.3 (0.69)	87.8
Zhou (a) et al 2	023 (RCT) <sup>37</sup>					
20	Intervention (RLRL)	3-16	9 (37.5)	-2.93 (1.87)	24.6 (1.16)	96.0
15	Control (SVS)	3-16	7 (41.2)	-2.11 (1.21)	24.4 (0.87)	76.0
Zhou (b) et al 2	023 (RCT) <sup>38</sup>				·	
43	Intervention (RLRL 0.37mW)	6-15	20 (40.0)	-1.72 (0.91)	24.2 (0.79)	86.0
47	Intervention (RLRL 0.60mW)	6-15	25 (50.0)	-2.01 (0.87)	24.1 (0.88)	94.0
44	Intervention (RLRL 1.20mW)	6-15	24 (48.0)	-2.08 (1.33)	24.5 (0.91)	88.0
43	Control (SVS)	6-15	21 (42.0)	-2.10 (0.90)	24.4 (0.90)	86.0
Tian (a) et al 20	)23 (RCT) <sup>39</sup>				·	
56	Intervention (RLRL)	6-12	33 (58.9)	0.25 (0.25)	23.1 (0.80)	100
		6-12	31 (55.4)	0.25 (0.19)	23.1 (0.70)	100

41	Intervention (RLRL)	6-18		-3.20 (2.82)	24.3 (1.04)	58.6
58	Intervention (RLRL)	6-18	84 (51.2)	-7.93 (2.95)	25.7 (1.57)	82.9
65	Control (SVS)	6-18		-2.32 (2.64)	24.3 (1.21)	92.9
Zhao et al 2023 (	non-randomized controlled trial) <sup>42</sup>				,	
47	Intervention (RLRL)	6-18	18 (38.3)	-2.31 (1.26)	24.6 (0.88)	100
20	Control (SVS)	6-18	8 (40.0)	-2.75 (0.84)	24.8 (0.90)	100
Wang et al 2023	(retrospective study) <sup>46</sup>					
434	Intervention (RLRL)	3-17	200 (46.1)	-3.74 (2.60)	24.9 (1.20)	-
Liu et al 2023 &	Tian (b) et al 2023 (case report) <sup>47,48</sup>				,	
1	L ( (DI DI )	12	1 (100)	OD -6.75D		
1	Intervention (RLRL)			OS -6.25D	-	-
Liu (a) et al 2024	(RCT) <sup>40</sup>					
47	Intervention (RLRL)	7-12	19 (44.2)	0.17 (0.35)	23.6 (0.78)	91.5
47	Control (SVS)	7-12	20 (47.6)	0.30 (0.35)	23.3 (0.73)	89.4
Liu (b) et al 2024	(single-arm study) <sup>45</sup>				,	
40	Intervention (RLRL)	7-14	17 (42.5)	-2.75 (1.43)	24.9 (0.97)	100
Xiong et al 2024	(non-randomized controlled trial) <sup>43</sup>				,	
45	Intervention (RLRL)	7-16	22 (48.9)	-3.00 (0.90)	23.6 (0.35)	100
45	Control (SVS)	7-16	23 (51.1)	-3.02 (0.11)	23.6 (0.37)	100
Zhang et al 2024	(non-randomized controlled trial)*44				,	
44	Intervention (RLRL)	≥7	25 (56.8)	-1.87 (1.16)	24.1 (0.80)	100

32	Intervention (OK)	≥7	14 (43.8)	-2.44 (1.15)	24.2 (0.73)	100
29	Intervention (RLRL+OK)	≥7	10 (34.5)	-2.55 (1.32)	24.5 (0.96)	100
36	Control (SVS)	≥7	18 (50.0)	-2.11 (1.11)	24.3 (0.82)	100

<sup>\*</sup> Only eye number for each group and total participant number was available in the publication.

Data were presented as number (percentage) or mean (standard deviation).

RLRL=repeated low-level red-light; SVS=single vision spectacles; RCT=randomized controlled trial; SER= spherical equivalent refraction; AL=axial length; OK=orthokeratology.

Table 2. Visual function, ocular structures and adverse events reported in RLRL studies.

Study	Follow-up (mo)	Visual function outcome	Ocular Structural Outcome	Adverse events
Jiang et al 2021 <sup>8</sup>	12	108 (97.3%) participants achieved	No structural damage on	· No adverse events were reported,
		BCVA of 20/20, and the BCVA in	photosensory layer was	including glare, flash blindness, or
		the remaining 3 (2.7%) participants	identified by OCT. (n=72)	afterimages.
		was 20/25. *		· No severe adverse events developed,
				including sudden vision loss by 2 lines
				occurring in a period of a few second/s or
				minutes to a few days or scotoma.
Yan et al 2021 <sup>33</sup>	12	-	-	• No ocular adverse events were reported,
				including conjunctival hyperemia,
				edema, photophobia, tears, corneal
				epithelial damage, lens opacity, macular
				damage.
				• No cognitive impairment and behavioral
				abnormalities were found.
Xiong et al 2022 <sup>9</sup>	12	10 (100%) participants maintained	No structural damage on	• No severe adverse events or side effects
		BCVA of 20/20.	photosensory layer was	including sudden vision loss of more than
			identified by OCT.	two lines, scotoma, dazzling, short-term
				glare, flash blindness, and afterimages
				developed.
Xiong et al 2022 <sup>9</sup>	24	11 (100%) participants maintained	No structural damage on	No severe adverse events or side effects

		BCVA of 20/20.	photosensory layer was	including sudden vision loss of more than
			identified by OCT.	two lines, scotoma, dazzling, short-term
				glare, flash blindness, and afterimages
				developed.
Dong et al 2022 <sup>11</sup>	6	-	-	18 adverse events were reported in 13
				participants, but none were related to
				RLRL therapy. †
Chen (a) et al	12	58 eyes (100%) maintained BCVA	No structural damage was	• No severe adverse events were reported,
2022 <sup>34</sup>		of 20/20.	identified by OCT.	including blindness, death,
				hospitalization, or conditions requiring
				medical or surgical interventions.
				· No adverse events including a sudden
				vision loss of two lines or more, a
				scotoma, photophobia, allergy, dry
				mouth, or tachycardia developed.
				• 1 participant reported dizziness after the
				red-light therapy, but the symptoms
				resolved after a few minutes and only
				occurred in the immediate post-treatment
				period for a few days.
Chen (b) et al	12	BCVA remained normal at each	No structural damage	No adverse events including dazzling,
2022 <sup>35</sup>		follow-up visit.	including vitreomacular	glare, long-term afterimages, and flash
			traction, macular schisis,	blindness were reported.

		<del>_</del>		
			macular hole, intraretinal	
			fluid, subretinal fluid,	
			hemorrhage, retinal pigment	
			epithelium proliferation, and	
			atrophy was identified by	
			OCT.	
Tian et al 2022 <sup>36</sup>	6	-	-	No adverse events including
				photophobia, eye itching, burning
				sensation, dry eye, blurred vision, glare,
				dazzling, keratitis, and conjunctivitis
				were reported.
He et al 2023 <sup>10</sup>	12	123 (100%) participants achieved	No structural damage	No adverse event was reported, including
		BCVA of 20/25.	including vitreomacular	glare, flash blindness, or afterimages
			traction, macular schisis,	longer than 6 minutes after treatment. ††
			macular hole, intraretinal	
			fluid, subretinal fluid,	
			hemorrhage, retinal pigment	
			epithelium proliferation, and	
			atrophy was identified by	
			OCT.	
Zhou (a) et al	12	No BCVA indicated visual function	No structural damage was	• Reversible subjective symptoms without
2023 <sup>37</sup>		loss.	identified by OCT.	objective ocular abnormalities (CTCAE
				grade 1) ‡, including reversible vision

				loss lasting $2.1 \pm 0.7$ min (n=23) after red-light therapy due to flash blindness or glare with afterimage, and afterimage with an average of $3.2 \pm 1.2$ min.  • No dry eye, cataract, keratitis, night blindness, photophobia or any other permanent visual impairment.  • No systemic adverse effects (such as headache or dizziness), severe adverse events, or other adverse events related to grades of ocular diseases: Grade 2–5 of CTCAE.
Zhou (b) et al 2023 <sup>38</sup>	6	BCVA remained normal at each follow-up visit.	No retinal or choroidal structural abnormalities were identified by OCT.	No adverse events were reported.
Tian (a) et al 2023 <sup>39</sup>	6	-	-	No adverse events were reported.
Lin et al 2023 <sup>41</sup>	2	-	-	· Afterimage is the most common phenomenon post RLRL therapy, which can be alleviated by a short period of eye-closing and rest; with the progression of treatment, this phenomenon does not appear to worsen.

				· No adverse events were reported.
Zhao et al 2023 <sup>42</sup>	1	-	No retinal structure related	-
			photodamage was identified	
			by OCT.	
Wang et al 2023 <sup>46</sup>	At least 12	-	-	No adverse events were reported.
Liu et al & Tian	5	· Binocular BCVA declined from	· Bilateral foveal ellipsoid	Prolonged afterimages after light therapy
(b) et al 2023 <sup>47,48</sup>		20/20 to 20/30. §	zone disruption and	(occasionally exceeding 8 minutes).
		·Multifocal electroretinogram	interdigitation zone	
		revealed the response of the central	discontinuity were identified	
		macula (ring 1) was moderately	by OCT. §	
		decreased and the response of	<ul> <li>Fundus photographs</li> </ul>	
		paramacula (ring 2 and 3) was	revealed bilaterally darkened	
		mildly decreased in both eyes.	foveae with a	
			hypoautofluorescent plaque	
			in autofluorescence images.	
Liu (a) et al	12	No BCVA indicated visual function	No structural damage was	No adverse events were reported.
$2024^{40}$		loss.	identified by OCT.	
Liu (b) et al	6	-	No change in macular	No adverse events were reported.
2024 <sup>45</sup>			structure or microcirculatory	
			system was identified by	
			OCT and OCTA.	
Xiong et al 2024 <sup>43</sup>	6	-	No ocular surface damage	No adverse events were reported.

			was found, and no structural	
			damage or macular	
			hemorrhage was identified by	
			OCT.	
Zhang et al 2024 <sup>44</sup>	6	BCVA remained unchanged at each	No structural damage within	No adverse events were reported.
		follow-up visit compared to	6mm macular region was	
		baseline.	identified by OCT.	

RLRL=repeated low-level red-light therapy; mo=month; BCVA=best corrected visual acuity; OCT=optical coherence tomography.

- †18 adverse events included one case each of influenza, an eyelid injury requiring surgical repair, and acute mesenteric lymphadenitis; two cases each of earwax blockage, and allergic rhinitis; and three cases of dental caries.
- ††Two participants dropped out due to the afterimage duration exceeded 6 minutes at baseline.
- ‡Common Terminology Criteria for Adverse Events (CTCAE) grade 1 refers to mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated.
- §After 3 months without RLRL therapy, the bilateral outer retinal damage partially recovered, and the visual acuity improved to 20/25 in both eyes. After 4 months discontinued RLRL therapy, the bilateral outer retinal damage totally recovered.

<sup>\*</sup>In the SVS control arm, the proportion of compromised BCVA 20/25 was 8 of 112 (7.1%).

**Table 3.** Estimated NNH and NNH/NNT ratios associated with RLRL therapy.

Variable	Multiplier	Value*
Annual incidence of vision loss		8.77
Years of vision loss accrued	× 65 years	570
NNH†		
For 1 year of vision loss	10,000/years vision loss	17.5
For 5 years of vision loss	$5 \times 10,000$ /years vision loss	87.7

<sup>\*</sup> We assumed that the annual incidence of vision loss from RLRL therapy as 8.77 per 10,000 patient-years. Any vision loss is estimated to be experienced for 65 years after the event.

All values are presented per 10,000 patients.

RLRL=repeated low-level red-light; NNH=number needed to harm; NNT=number needed to treat.

<sup>†</sup> The NNH/NNT ratios are 12.7-fold for -3D, 14.4-fold for -4D, 16.4-fold for -5D, 18.1-fold for -6D, 19.9-fold for -7D and 21.4-fold for -8D with RLRL therapy.

medRxiv preprint doi: https://doi.org/10.1101/2024.04.19.24306057; this version posted April 19, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Table 4. Comparison of the ocular adverse event incidence rate between RLRL and other interventions.

Interventions	Baseline age	Number of	Person- years	Ocular adverse	Ocular adverse events per	95% CI*
	criteria (years)	participants		events	100 patient-years	
RLRL <sup>8-11,33-48</sup>	3-18	1436	1139.8	1	0.088	0.02-0.50
Low-dose atropine <sup>60-78</sup>	4-16	2736	5368	393	7.32	6.65-8.05
Orthokeratology <sup>76,79-84</sup>	6-12	231	364.5	75	20.6	16.7-25.0
Anti-myopia contact lens <sup>85-90</sup>	7-15	697	1899	366	19.3	17.6-21.1
Spectacles designed for myopia reduction <sup>49-59</sup>	6-16	1247	2299	5	0.22	0.09-0.51

RLRL=repeated low-level red-light; CI=confidence interval.

Anti-myopia contact lens includes rigid gas permeable contact lens and soft multifocal contact lens. Spectacles designed for myopia reduction includes bifocal lens, progressive addition spectacles, aspherical lenslets and peripheral defocus spectacles.

\*95% CI was calculated using Wilson methods.